Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down

Acadia Pharmaceuticals Inc. (ACAD) reported fourth-quarter 2023 earnings of 28 cents per share, missing the Zacks Consensus Estimate of 32 cents. In the year-ago quarter, the company had incurred a loss of 26 cents per share.The bottom line improved year over year owing to higher product sales.The company recorded total revenues of $231 million in the fourth quarter, surpassing the Zacks Consensus Estimate of $223 million. Acadia’s net product revenues comprise revenues generated from the sale of its two ma ...